SCHEMBL2657564

SCHEMBL2657564

CC(C)COc1cc(C(=O)Nc2ccc(P(=O)(O)O)cn2)cc(OC(C)C)n1

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GCK P35557 20/20 0.56
RARA P10276 2/20 0.56
RARB P10826 2/20 0.56
RARG P13631 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2669830 0.93 GCK (0.50) GCKRARARARBRARG
SCHEMBL2667949 0.86 GCK (0.74) GCKRARARARBRARG
SCHEMBL12021289 0.84 GCK (0.74) GCKRARARARBRARG
SCHEMBL12021209 0.80 GCK (0.62) GCKRARARARBRARG
SCHEMBL12021261 0.78 GCK (0.73) GCKRARARARBRARG
SCHEMBL12021393 0.76 GCK (0.59) GCKRARARARBRARG
SCHEMBL2667503 0.74 GCK (0.78) GCKRARARARBRARG
SCHEMBL2667505 0.74 GCK (0.78) GCKRARARARBRARG
SCHEMBL2656899 0.74 GCK (0.62) GCKRARARARBRARG
SCHEMBL9070974 0.74 GCK (0.62) GCKRARARARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174062-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2019-01-08 US disclosed
US-10005805-B2 2018-06-26 US disclosed
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. 2017-04-06 US disclosed
CN-106279283-A Novel activators of glucokinase 症变治疗公司 2017-01-04 CN disclosed
US-9522926-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2016-12-20 US disclosed
CN-101821276-B Novel glucokinase activators 症变治疗公司 2016-08-31 CN disclosed
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-04-30 US disclosed
US-8940927-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2015-01-27 US disclosed
EP-2185570-B1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS INC (US) 2014-03-19 EP disclosed
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2011-12-01 US disclosed
EP-2185570-A2 NOVEL ACTIVATORS OF GLUCOKINASE Metabasis Therapeutics, Inc. (US) 2010-05-19 EP disclosed
WO-2009023718-A2 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005805-B2 GCKR, GCK, HK1 GCK 2/4885RARA 4038/4885RARB 4520/4885
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 GCK 2/4885RARA 3930/4885RARB 4546/4885
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 GCK 2/4885RARA 3930/4885RARB 4546/4885
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 GCK 2/4885RARA 3930/4885RARB 4546/4885
US-10174062-B2 Activators of glucokinase GCKR, GCK, HK1 GCK 2/4885RARA 3781/4885RARB 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.